FDA Warns of Serious Risks Associated With Novo Nordisk A/S (NVO)'s Victoza  
6/14/2011 8:37:51 AM

Novo Nordisk announced today the issuance of a letter to health care providers, as required by a Risk Evaluation and Mitigation Strategy, reminding them of important safety information associated with liraglutide injection. According to the FDA, a recent evaluation showed that some primary care providers are unaware of the serious risks associated with liraglutide (Victoza).